Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy

Annals of Oncology

Volumn 10, Issue 10, 1999, Pages 1249-1250

  Korte, W ^a   Jost, C ^a   Cogliatti, S ^a   Hess, U ^a   Cerny, T ^a,b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b Kantonsspital   (Switzerland)

Author keywords

CD20; IL 6; Monitoring; Multiple myeloma

Indexed keywords

ALPHA INTERFERON; CD20 ANTIGEN; CYCLOPHOSPHAMIDE; EPIRUBICIN; INTERLEUKIN 6; MELPHALAN; PAMIDRONIC ACID; PARAPROTEIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CASE REPORT; DETERIORATION; DRUG EFFICACY; HUMAN; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MULTIPLE MYELOMA;

EID: 0032744428     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008310819049     Document Type: Article

References (12)

1. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
2. Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. 1DEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 3266-74.
3. Jensen M, Winkler U, Manzke O et al. Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab). Ann Hematol 1998; 77: 89-91.
4. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-32.
5. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91:1644-52.
6. Taji H, Kagami Y, Okada Y et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998; 89: 748-56.
7. Kyrstsonis MC, Dedoussis G, Baxevanis C et al. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol 1996; 92: 420-2.
8. Ghetie MA, Podar EM, Ilgen A et al. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc Natl Acad Sci USA 1997; 94: 7509-14.
9. Holder M, Grafton G, MacDonald I et al. Engagement of CD20 suppresses apoptosis in germinal center B cells. Eur J Immunol 1995; 25: 3160-4.
10. Greipp PR, Lust JA. Pathogenetic relation between monoclonal gammopathies of undetermined significance and multiple myeloma. Stem Cells (Dayt) 1995; 13 (Suppl 2): 10-21.
11. Beschorner R, Horny HP, Petruch UR, Kaiserling E. Frequent expression of haemopoietic and non-haemopoietic antigens by reactive plasma cells: An immunohistochemical study using formalin-fixed, paraffin-embedded tissue. Histol Histopathol 1999; 14: 805-12.
12. Maloney DG, Donovan K, Hamblin TJ. Antibody therapy for treatment of multiple myeloma. Semin Hematol 1999; 1 (Suppl 3): 30-3.